Dignify Therapeutics, a company developing pharmaceutical products to treat bladder and bowel dysfunction, has established offices in the at Research Triangle Park startup incubator First Flight Venture Center.

Dignify, a virtual company, was incorporated last June. The company is focused on restoring voluntary control of excretory function to people with spinal injury and other neurological conditions.

“We are pleased to be immersed in an environment that surrounds us with the enthusiastic atmosphere generated by other entrepreneurs,” Dr. Karl Thor, Dignify’s president and co-founder, said in a statement. “The support and guidance we receive from the senior management and entrepreneurs-in-residence at the First Flight Venture Center is highly valuable as we progress our ideas from the lab into the clinic.”

Dignify pegs the U.S. incontinence products market at $19 billion. The company’s lead development program is DTI-100, a compound being developed to treat urinary retention in people with spinal cord injury. The drug is intended to reduce or replace use of bladder catheters, in turn reducing health care costs.

Dignify has other drug programs to treat bladder and bowel dysfunction in patients who have spina bifida, multiple sclerosis, stroke, Parkinson’s disease and diabetes.